Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders.
Cabaletta Bio Inc. has announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain.
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
Eli Lilly & Co. has identified new fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of achondroplasia, cancer, pulmonary fibrosis, systemic scleroderma and thanatophoric dysplasia, among other disorders.
A simple injection of muscle tissue could control glucose in patients with type 2 diabetes (T2D). Genetic modification of skeletal muscle and subsequent intramuscular implantation could increase blood sugar absorption and become an effective and long-lasting treatment for this pathology. “We took mice satellite cells and we genetically altered to overexpress GLUT4,” Hagit Shoyhet, researcher at the Levenberg lab of stem-cell and tissue engineering, Technion (Israel), said at the European Association for the study of Diabetes (EASD) 58th Annual Meeting.
The Royal Veterinary College has presented drug conjugates comprising hyaluronan (HA) synthesis inhibitors covalently bonded to betaine reported to be useful for the treatment of chondrosarcoma and osteoarthritis.
Following a research program to identify inhibitors of protein kinases TBK1 and IKK-ε, Domainex Ltd. has nominated DMXD-011 as a preclinical drug candidate.
Wellstat Therapeutics Corp. has described compounds for co-delivery of uridine and ketoleucine with high bioavailability reported to be useful for the treatment of muscle atrophy, sarcopenia and cachexia.
Gilead Sciences Inc. has described thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among other disorders.
Structure-guided design for carbazole antagonists of Toll-like receptors 7 and 8 (TLR7/8) for the potential treatment of autoimmune disorders was reported by Bristol Myers Squibb Co. TLR activation can induce proinflammatory pathway activation, which has been identified in patients with lupus.
RSS
